Two new classes of drugs glucagon-like peptide 1 receptor agonists (GLP1Ra) and SGLT2 inhibitors might change the trajectory of lethal synergy for T2DM and HF. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.